Pulmatrix has stopped acting like a drug developer and started acting like a public listing in search of a private tenant. After the prior reverse-merger partner walked away, the board signed a new all-stock combination that hands control of the Nasdaq vehicle to Eos SENOLYTIX, a Houston gerotherapeutics shop built around mitochondrial peptides. Legacy common is slated to keep only a thin stub of the combined company. The investment debate is whether that stub, plus any leftover value in paused inhalation assets, is worth more than a wind-down of a cash-light shell.
The second-quarter print is a maintenance-mode snapshot, not a pipeline update. Unrestricted cash sat at $2.2 million at period end, with another slice held as restricted proceeds from an Eos-affiliate preferred placement. Operating spend is almost entirely general and administrative. Research outlays have effectively ceased while the company shops the three named inhalation candidates. The economics that matter sit in the exchange ratio. Pre-combination Eos holders, financing investors, and fee recipients are expected to own about 94% of the surviving entity. Existing Pulmatrix holders are left near 6%.
That split is the price of remaining listed. The August results release and the amended registration materials frame cash as enough to reach an anticipated close, and they also state substantial doubt about continuing as a going concern if the combination does not close. The board has already named dissolution as a live alternative. The question the next several weeks resolve is whether stockholders approve the share issuance, the name change, and a reverse split sized to satisfy the Nasdaq bid-price test for the surviving listing.